Management of Mucinous Breast Carcinoma in Postmenopausal Women

Introduction to Management

Mucinous breast carcinoma should be managed identically to invasive ductal carcinoma using the same evidence-based treatment algorithms, determined by tumor size, lymph node status, and hormone receptor status—not by the mucinous histology itself, as recommended by the American College of Surgeons 1, 2

Breast-conserving surgery with radiation therapy is the preferred approach for most patients with mucinous carcinoma, as it provides equivalent survival to mastectomy with superior quality of life, according to the American Cancer Society 1
Mastectomy with immediate reconstruction should be offered when breast conservation is not feasible or patient-preferred, as suggested by the American Society of Breast Surgeons 1

Whole breast radiation therapy after lumpectomy is mandatory, as it substantially reduces local recurrence and improves survival, as recommended by the American Society for Radiation Oncology 1

Aromatase inhibitors are the preferred initial adjuvant endocrine therapy in postmenopausal women, superior to tamoxifen alone, as recommended by the National Comprehensive Cancer Network 3, 2
Duration of 5 years minimum of endocrine therapy is standard, as suggested by the British Journal of Cancer 4, 5
Sequential or extended strategies are acceptable alternatives, as recommended by the American College of Physicians 2

For node-positive disease, chemotherapy is mandatory, followed sequentially by endocrine therapy, as recommended by the National Comprehensive Cancer Network 6, 2
If chemotherapy is indicated, sequential anthracycline-cyclophosphamide followed by taxane regimens are standard, administered for 4-8 cycles before initiating endocrine therapy, as suggested by the American Society of Clinical Oncology 2
Never administer tamoxifen concurrently with chemotherapy, as this reduces disease-free survival, as recommended by the American College of Clinical Oncology 2

Treatment must be delivered by a specialized breast team including medical oncologist, breast surgeon, radiation oncologist, breast radiologist, and breast pathologist, as recommended by the American College of Surgeons 1

Do not omit radiation therapy after breast-conserving surgery based on favorable mucinous histology, as warned by the American Society for Radiation Oncology 1
Do not use tamoxifen alone in postmenopausal women when aromatase inhibitors are available and superior, as recommended by the National Comprehensive Cancer Network 2
Do not withhold chemotherapy in node-positive disease solely because of favorable mucinous biology, as warned by the American Society of Clinical Oncology 2
Do not accept positive surgical margins—re-excision is required, as recommended by the American College of Surgeons 1